Carrier-antibody compositions and methods of making and using the same
US-10300016-B2 · May 28, 2019 · US
Methods and compositions for treating cancer with ECM-affinity peptides linked to cytokines
US12365714B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12365714-B2 |
| Application number | US-201915733582-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 5, 2019 |
| Priority date | Mar 5, 2018 |
| Publication date | Jul 22, 2025 |
| Grant date | Jul 22, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating cancer in a subject comprising administering a polypeptide comprising IL-12 conjugated to the collagen binding domain of SEQ ID NO:3 or 34 to the subject; wherein the cancer comprises colon, breast, prostate, pancreatic, glioblastoma, ovarian, or head and neck cancer. 2. The method of claim 1 , wherein the polypeptide comprising IL-12 is at least 85% identical to SEQ ID NO:37 or SEQ ID NO:35. 3. The method of claim 1 , wherein the subject is being treated with a checkpoint inhibitor. 4. The method of claim 3 , wherein the checkpoint inhibitor comprises and anti-PD-1, an anti-PD-L1, an anti-CTLA-4 antibody, or combinations thereof. 5. The method of claim 4 , wherein the checkpoint inhibitor comprises an i) an anti-PD-1 or anti-PD-L1 and ii) an anti-CTLA-4 antibody.
Assignees
Inventors
Classifications
Fusion polypeptide · CPC title
- C07K14/755Primary
Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)} · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
IL-2 · CPC title
Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12365714B2 cover?
- The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to …
- Who is the assignee on this patent?
- Univ Chicago
- What technology area does this patent fall under?
- Primary CPC classification C07K14/755. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).